bullish messag
aao reiter ow rais pt
exit posit strength follow year peer-high organ
growth oper margin expans despit meaning acquisit dis-
synergi coupl first-tim guidanc came expect
top bottom surpris compani current one best
perform large-cap name med-tech coverag ytd bullish
manag dinner booth tour investor meet even confid
sustain kind momentum balanc
healthi level multipl top-lin growth driver tap room
meaning margin expans mind reiter overweight
rate stock rais target-price cash ep
justifi premium peer current trade ntm
manag highlight solid mix tailwind make
organ guidanc mere baselin continu share captur knee
drive anoth year double-digit mako instal healthi capit environ
medsurg coupl launch endoscopi easi comp
 physio-control grow dd new product launch spine
grow msd pro-forma compani aim stabil us salesforc earli
anoth year double-digit growth neurovascular continu
ischem stroke market expans earli benefit new product launch
start mako expect compani drive anoth year double-
digit robot placement manag clear worri
continu offenc competit
hospit current penetr multipl mako system
clear think rosa gain traction dedic zimmer biomet
doc think itll take time market under-penetrated
there plenti room move aggress meantim
challeng launch robot also near-term headwind rosa
zimmer biomet establish dedic salesforc new zimmer
connect ecosystem solut initi sale pitch actual made
exist ortho rep rememb initi mako knee launch ran struggl
even dedic capit salesforc wasnt meaning
expand roster mako specialist launch realli abl take
page analyst certif import disclosur
 morgan seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report singl
factor make invest decis
coupl continu cementless adopt see anoth year msd
knee growth continu success leverag mako increas
cementless percentag tka mix believ could ultim reach
high mix cementless knee requir maximum amount surfac
contact enabl boni ingrowth someth enabl robot system
zimmer current process launch cementless offer
expect see meaning benefit sale zimmer establish larger instal
base robot even remain seen whether rosa
built-in saw abl match cut made mako taken
account model stryker global knee franchis grow us growth
look balanc ortho hip improv trauma
extrem remain strong unsurprisingli valu proposit mako hip
compel given significantli better outcom associ tradit
tha vs tka near-term launch print acetabular cup drive
growth market longer term opportun come improv
registr process current slower hip knee
target apac market like china japan higher incid
dysplasia sever deform move expect see anoth
year msd-hsd growth compani upper portfolio boost addit
short-stem shoulder portfolio
move medsurg manag see continu healthi capital-expenditure environ
head hospit consolid compani continu see larger
deal commensur slower product cycl work deal
howev import note hospit like spend moneymak like
surgeri far less expos capital-expenditure year ago due
consum orient acquisit made recent year
medsurg busi expos today
new product launch across portfolio coupl anoth year
easi comp instrument moder
enter third year market still expect anoth year hsd organ
growth ex-invu endoscopi camera move limit
launch full launch end quarter second year new camera
launch gener fastest still model hsd growth busi easi
us comp close medic see legaci busi
benefit aforement healthi capital-expenditure environ physio-control
grow dd back new approv late
continu recoveri benefit easi comp benefit
custom work-down competitor inventori
integr key stryker spine outlook go forward
manag reiter outlook pro-forma growth
broader spine market wide seen unattract argu
largest ortho market one reli similar platform technolog balanc
ortho bring meaning portfolio upgrad
abl leverag significantli larger salesforc drive cross-sel
combin portfolio overlap two portfolio us
sale forc integr expect complet earli confid
manag learn mistak past spine integr pois
meaning upgrad spine busi
neurotech also posit anoth strong year new product
like stori underli ischem stroke market pois
grow healthi dd player benefit dawn work expand market
except benefit continu uptak trevo howev
compani also receiv approv aspir cathet
expect gradual roll-out given one cathet brought
acquisit current indic medela pump similarli
launch compani new surpass flow divert stent also take longer roll
though bigger long-term opportun two mechan action
differ wire versu empti cathet requir
physician proctor first case told see neurotech slow
modestli still grow healthi ldd
final worth touch someth realli becom core
compet stori almost given make
number revenu growth-accret acquisit given year compani
close three notabl tuck-in acquisit cours two smaller deal
announc alreadi deal key piec stryker
continu outperform expect grow med-tech averag
compani realli abl develop expertis integr quickli
captur synergi saw oper margin
expand even acquisit relat dis-synergi expect
see even continu invest ctg integr
told believ look anoth standout year headlin hsd
organ growth dd ep growth balanc mix tailwind across
breadth portfolio see grow minimum organ
msd growth ortho hsd growth medsurg hsd growth neurotech
spine expect see oper margin expans
benefit synergi captur ctg indirect spend share servic off-set
integr spend continu invest longer term ctg program
like erp plcm lead us model cash ep full
year final rais target-price per share notabl
premium peer trade ntm one that well deserv given
compani above-p growth profil expertis integr
invest thesi valuat risk
one premium growth stori med-tech univers see
come compani end organ sale
growth notabl step peer see multipl top-lin driver
go new product launch track begin endoscopi
neurotech physio-control benefit recent novadaq entellu
continu momentum knee instrument neurotech told
lead anoth year organ out-performance sustain top-lin
growth versu peer closer line expect anoth year
meaning oper margin improv despit dilut
invuiti compani continu benefit ctg program
addit margin expans top peer-high growth rate remain
bullish abil outperform expect expect
stock trade multipl reflect compani premium top- bottom-lin
outlook forese futur remain one expens name
group clear path out-performance ahead remain
dec price target share valu stock project
earn outlook premium large-cap peer admittedli one
expens stock group view worth
problem trade premium peer
risk rate price
downsid risk rate price target includ slower growth key end
market increas competit price pressur downturn us capit
equip spend dilut
stryker corp summari financi
cash equival
flow oper activ
o/w chang work capit
flow invest activ
sale
flow financ activ
net chang cash
adj free cash flow firm
compani report morgan estim
note million except per-shar data fiscal year end dec o/w
analyst certif author name within report research analyst unless otherwis specifi research analyst
denot ac cover report certifi multipl research analyst primarili respons report
research analyst denot ac cover within document individu certifi respect secur issuer
research analyst cover research view express report accur reflect person view
subject secur issuer part research analyst compens
directli indirectli relat specif recommend view express research analyst report korea-
base research analyst list front cover also certifi per kofia requir analysi made good faith
view reflect opinion without undu influenc intervent
